VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 3, 2026
Stock Comparison
AstraZeneca PLC vs Fair Isaac Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisFair Isaac Corporation
FICO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Fair Isaac Corporation's moat claims, evidence, and risks.
View FICO analysisComparison highlights
- Moat score gap: Fair Isaac Corporation leads (82 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Fair Isaac Corporation has 2 segments (58.7% in Scores).
- Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Strong vs Strong.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Fair Isaac Corporation has 5 across 2.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Fair Isaac Corporation
Scores
Consumer credit scoring and related predictive scores used in lending decisions
Primarily United States; also international
Lenders (mortgage, credit card, auto, etc.), consumer reporting agencies, and consumers (B2C)
Score model developer/licensor; distribution via consumer reporting agencies and direct-to-consumer channels
58.7%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Fair Isaac Corporation strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Fair Isaac Corporation segments
Full profile >Scores
Quasi-Monopoly
Software
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.